Analysis of Pharmacodynamic Changes Associated With the Administration of the Heat Shock Protein 90 Inhibitor AUY922A in Patients With Advanced Solid Malignancies.
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Luminespib (Primary)
- Indications Solid tumours
- Focus Biomarker; Pharmacodynamics
- 15 Mar 2010 Dosing has been initiated in the phase II proof-of-concept portion of this trial, according to a Vernalis media release. Results from phase II are expected in 2010.
- 05 Dec 2009 New trial record